Welcome to our dedicated page for OneMedNet news (Ticker: ONMD), a resource for investors and traders seeking the latest updates and insights on OneMedNet stock.
OneMedNet Corporation (NASDAQ: ONMD) is frequently featured in news coverage for its role as a curator and provider of regulatory-grade, AI-ready Real-World Data through its iRWD™ platform. Company announcements highlight developments across its healthcare provider network, subscription offerings, technology partnerships, and relationships with life sciences, medical device, and healthcare AI organizations.
News about OneMedNet often focuses on expansion of its iRWD™ network, including increases in the number of provider sites, de-identified patient records, and clinical exams available for research and analytics. The company also reports on new subscription agreements and master service arrangements that provide customers with ongoing access to curated, multimodal datasets for AI model development, Real-World Evidence programs, and clinical research.
Another key theme in OneMedNet’s news flow is its collaboration with Palantir Technologies. Press releases describe how Palantir’s Artificial Intelligence Platform and Foundry environment are integrated with OneMedNet’s network to enable faster cohort discovery, AI-driven de-identification, and natural-language search across regulatory-grade Real-World Data. Coverage of industry events such as RSNA and ISPOR Europe frequently includes demonstrations of OneMedNet’s redesigned data exploration and cohort-building platform.
Investors and analysts following ONMD can also find updates on strategic partnerships, such as the company’s collaboration with Medcase in healthcare data annotation, and commentary on trends in demand for large-scale Real-World Data subscriptions. For a consolidated view of these developments, the ONMD news page on Stock Titan aggregates press releases, event-related updates, and other public communications so readers can review how OneMedNet’s strategy and operations are being presented over time.
OneMedNet (NASDAQ:ONMD) has selected Inka Health, a subsidiary of Onco-Innovations, to spearhead an AI-driven oncology data analytics project focused on developing external control arms (ECAs) for clinical trials. The initiative aims to leverage OneMedNet's iRWD Real-World Data platform to create more efficient alternatives to traditional clinical trials.
The project will utilize Inka Health's SynoGraph platform, combining machine learning with causal inference methods, to validate an ECA for the Keynote-189 trial of pembrolizumab in non-small cell lung cancer. This collaboration targets the Real-World Evidence (RWE) market, projected to reach $4.6 billion by 2030, and aims to accelerate cancer therapy development while reducing costs.
Onco-Innovations Limited (OTCQB:ONNVF) announced that its subsidiary Inka Health has been selected by OneMedNet (Nasdaq:ONMD) to lead an AI-driven oncology data analytics initiative. The project aims to develop external control arms (ECAs) using OneMedNet's regulatory-grade patient data to accelerate cancer therapy development.
The collaboration will utilize Inka Health's SynoGraph platform to validate an ECA for the Keynote-189 trial of pembrolizumab in non-small cell lung cancer. This initiative targets the Real-World Evidence (RWE) market, projected to reach $4.6 billion by 2030. The project aims to demonstrate how real-world data can replicate traditional clinical trial results more efficiently, potentially reducing development costs and timelines.
The companies plan to submit their findings to ISPOR Europe 2025, positioning themselves at the forefront of AI-driven oncology research and drug development.
OneMedNet (NASDAQ:ONMD), a leader in AI-powered Real-World Data (RWD), shared significant achievements in a shareholder letter from CEO Aaron Green. The company has expanded its iRWD™ platform to include five major data marketplaces and grown its network to over 121 million clinical exams across 1,400 healthcare providers.
Key developments include implementing a new subscription-based Data License Agreement model to drive Annual Recurring Revenue, expanding AI-powered de-identification capabilities beyond healthcare into finance, telecom, and retail sectors, and achieving a threefold increase in qualified leads to over 130. The company's datasets meet FDA and international standards, positioning OneMedNet to capture a share of the projected $60-110 billion annual value in pharmaceutical and medical-device sectors through generative AI and RWD.
OneMedNet (Nasdaq: ONMD), a provider of regulatory-grade imaging Real-World Data, has secured $3.7 million in funding through private placement transactions at $0.42 per share. The company has also significantly improved its financial position by reducing liabilities by approximately $11 million, representing a 60% reduction in total liabilities as of March 31, 2025.
The liability reduction includes settling $3.26 million in deferred underwriter fees, $1.08 million in trade payables, converting $6.56 million of principal and interest into common stock, and redeeming $250,000 in convertible notes. The company plans to use the new funding for working capital and general corporate purposes, while continuing its strategy of adding Bitcoin to its balance sheet.
OneMedNet (NASDAQ: ONMD), a provider of imaging Real-World Data (iRWD), has announced enhanced capabilities through the Datavant Connect platform and AWS Clean Rooms to improve healthcare data discovery and analytics. The integration will enable secure data collaboration environments without direct data movement, significantly improving data security and privacy while facilitating faster identification and evaluation of healthcare datasets.
The announcement comes as the healthcare industry faces challenges with the growing volume of health-related data, including genomic sequencing and biomarker data. The new platform will be showcased at ISPOR 2025, demonstrating OneMedNet's commitment to providing secure, scalable data solutions for healthcare and life sciences organizations.
OneMedNet (Nasdaq: ONMD) has integrated its imaging Real-World Data (iRWD) solution into the HealthVerity Marketplace, expanding access to comprehensive healthcare data for life sciences research. OneMedNet's network encompasses over 1,400 healthcare systems with access to 121 million clinical exams from 31 million unique patients.
This integration allows researchers to combine imaging data with medical claims, pharmacy, lab, and EHR data, providing a more complete view of patient journeys. The HealthVerity platform connects data from over 340 million de-identified individuals in a HIPAA-compliant environment.
The partnership enhances evidence generation capabilities by adding visual confirmation of disease progression, diagnostic markers, and therapy responses to structured data analysis. This collaboration aims to support more informed clinical development and commercialization decisions in healthcare research.
OneMedNet (ONMD) has announced a strategic partnership with Protege, an AI training data platform, to provide real-time access to multimodal patient data for AI developers and researchers. The collaboration will make OneMedNet's comprehensive healthcare datasets available through Protege's platform.
The partnership aims to enhance AI model development by providing access to diverse clinical data, including medical imaging, electrocardiograms (ECG), electroencephalograms (EEG), and other modalities. OneMedNet's iRWD™ platform currently leverages data from over 1,400 healthcare sites, covering areas such as rare diseases, oncology, and cardiology.
The company's technology extends beyond healthcare, offering AI anonymization services for industries like finance, retail, and telecom, enabling secure sharing of sensitive data by removing personal information.
OneMedNet has announced a strategic collaboration with Datavant to enhance access to tokenized healthcare data through Datavant's ecosystem. The partnership leverages OneMedNet's extensive network of 31 million patients and 121 million+ clinical studies, including EMR insights, images, ECGs, and clinical notes.
The integration enables life sciences companies to combine claims data for comprehensive patient journey analysis across specific diseases. By incorporating OneMedNet's patient tokens into Datavant's network of over 300 real-world data partners, researchers can efficiently discover and access targeted Real-World Data for specific patient populations. This collaboration aims to improve longitudinal data visibility and connectivity while maintaining patient privacy, ultimately accelerating evidence-based healthcare solutions.
OneMedNet (Nasdaq: ONMD) has appointed Dr. Kenneth Alleyne to its Board of Directors, where he will serve as Chair of the Audit Committee. Dr. Alleyne, a board-certified orthopedic surgeon specializing in sports medicine, brings significant healthcare, insurance, and corporate governance expertise to the company.
Dr. Alleyne is the managing partner of HartHaven Partners, a healthcare consulting firm. His entrepreneurial background includes co-founding NextLevel Health Partners and Zing Healthcare, focusing on Medicaid and Medicare Advantage initiatives. He was also a seed investor and founding chief medical officer of VirtualHealth, and co-founder/CEO of Fizio Health, an AI-powered remote physical therapy platform.
The appointment aims to enhance OneMedNet's iRWD™ platform, strengthen relationships with medical device companies in orthopedics, and provide insurance companies with insights for cost savings, particularly in high-spend orthopedic care.
OneMedNet (ONMD) has regained compliance with Nasdaq Listing Rule 5550(b)(2) after its common stock market value exceeded $35,000,000 for 10 consecutive business days. The company has cleared all listing deficiency notices issued by Nasdaq.
Throughout 2024-2025, OneMedNet implemented several strategic initiatives, including: expanding product offerings with data masking solutions and subscription-based services; appointing key executives including Bob Golden as CFO; signing an agreement with Bayer's AI Innovation Platform; enhancing data de-identification services with Generative AI; deploying the OMNi 2.0 indexer; refreshing the Board of Directors; and improving liquidity through $6.4M in private placements with Off the Chain Capital and Discovery Capital Management affiliate. The company also implemented a Bitcoin treasury management strategy.